Objective:To investigate the effects of orlistat combined with drospirenone/ethinylestradiol tablets(DRSP/EE)on anthropometric indices,sexual hormones,hepatorenal function parameters of overweight or obese patients with polycystic ovary syndrome(PCOS).Methods:75 overweight or obese PCOS patients[body mass index(BMI)＞24 kg/m2]were recruited within the Department of Gynecological Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical Uni-versity,from April 2019 to January 2020,for a prospective,randomized,open-labelled comparing study.They were numbered one by one according to the order of recruitement and randomly divided into two groups,group 1 included 50 patients,orlistat plus DRSP/EE;group 2 included 25 patients treated with DRSP/EE alone.Both groups got the same comprehensive intervention in terms of individualized,standardized managment and mon-itoring of life-style like diet and exercise.The changes of anthropometric indices,sexual hormones,hepatorenal function parameters before and after three months of treatment in the two groups were compared.Results:After three months of treatment,body weight,waist circumference(WC),hip circumference(HC)and BMI of both groups were significantly decreased(P＜0.05).The decrease of body weight,WC,HC and BMI in group 1 was significantly greater than those in group 2(P＜0.05).Free testosterone and sex hormone-binding globulin in both groups were significantly changed(P＜0.05).There was no significant difference in the hepatorenal function parameters between the two groups after three months treatment(P＞0.05).Conclusion:To our knowledge our study is the first to investigate the effects of orlistat combined with DRSP/EE in overweight or obese PCOS patients comparing with the effect of using DRSP/EE alone.Orlistat combined with DRSP/EE was better than use DRSP/EE alone in getting weight loss,which provides an evidence for the choice of rational drug use in clinical practice.

Department of Gynecological Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing Maternal and Child Health Care Hospital,Yaojiayuan Road 251,Beijing 100026,China;Department of Women's Health,University Hospital Tuebingen,Calwer Strasse 7,Tuebingen 72076,Germany

[1]Min Min;Xiangyan Ruan;Alfred O.Mueck-.Advanced therapy of overweight or obese polycystic ovary syndrome:a prospective study)[J].全球健康杂志（英文）,2022(02):75-79

orlistat,drospirenone,ethinylestradiol,DRSP,recruitement,managment,Orlistat

Advanced,therapy,overweight,obese,polycystic,ovary,syndrome,prospective,study,Objective,To,investigate,effects,combined,tablets,EE,anthropometric,indices,sexual,hormones,hepatorenal,function,parameters,patients,PCOS,Methods,body,mass,were,recruited,within,Department,Gynecological,Endocrinology,Beijing,Obstetrics,Gynecology,Hospital,Capital,Medical,Uni,versity,from,April,January,randomized,open,labelled,comparing,They,numbered,by,according,order,randomly,divided,into,two,groups,included,plus,treated,alone,Both,got,same,comprehensive,intervention,terms,individualized,standardized,itoring,life,style,like,diet,exercise,changes,before,after,three,months,treatment,compared,Results,After,waist,circumference,WC,hip,HC,both,significantly,decreased,was,greater,than,those,Free,testosterone,binding,globulin,changed,There,difference,between,Conclusion,our,knowledge,first,using,better,use,getting,loss,which,provides,evidence,choice,rational,drug,clinical,practice

0.460527